Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II treosulfan-based conditioning before allogeneic hematopoietic stem cell transplantation
2005-005182-11Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Mar 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan and fludarabine in hematopoietic malignancies, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 6 more, sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Engraftment and CTC grade 3 and 4 adverse events. Started Mar 2006; status: completed.
02
Drugs
treosulfanfludarabine
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-005182-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005182-11.